Phase 4: testing Nicotine patch for Smoking Cessation
The overarching goal of this program of research is to reduce smoking-related health disparities by increasing smoking cessation among Black adults. The goal of this research proposal is to determine whether more intensive, culturally specific, evidence-based interventions are more effective at promoting long-term cessation and other key patient-centered outcomes compared to the usual evidence-based standard of care: services provided by a state-run quitline.
Official registry: https://clinicaltrials.gov/study/NCT07419425 · University of Wisconsin, Madison · enrollment listed as 1,550
What this phase means
Phase 4: the treatment is already approved. This study asks new questions — longer-term effects, other diseases, or how it compares in everyday care.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are Nicotine patch, Quitline Counseling Phone Calls, or Counseling Sessions. The registry lists allocation as randomized. The overarching goal of this program of research is to reduce smoking-related health disparities by increasing smoking cessation among Black adults.
They plan to enroll about 1,550 people at 5 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
Official title (unrewritten)
Comparing Three Multicomponent Interventions to Help Adults Quit Smoking
Interventions: Nicotine patch, Quitline Counseling Phone Calls, Counseling Sessions, Pathways to Freedom, Monetary Incentive
Primary outcome (registry wording): Biochemically confirmed abstinence from combusted tobacco at 26-weeks post-target quit day
Who it is for (from inclusion criteria)
- Ages 21 Years to any
- self-identify as Black
- smoke cigarettes (greater than or equal to 1 cigarette on greater than or equal to 4 days/week)
- motivated to quit smoking
- willing to discontinue any non-study smoking cessation pharmacotherapy use during study treatment
Who the registry excludes
- currently taking bupropion for non-smoking cessation reasons
Public study contact (from the registry)
Megan Piper, PhD
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
5 listed- Arizona State University — Phoenix, Arizona (not_yet_recruiting)
- Indiana University — Indianapolis, Indiana (not_yet_recruiting)
- University of Kansas Medical Center Research Institute, Inc — Kansas City, Kansas (not_yet_recruiting)
- Virginia Commonwealth University — Richmond, Virginia (not_yet_recruiting)
- UW School of Medicine and Public Health — Milwaukee, Wisconsin (recruiting)
FAQ about this NCT record
Is NCT07419425 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07419425?
Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07419425?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary